Literature DB >> 8012971

Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.

H S Friedman1, M E Dolan, S H Kaufmann, O M Colvin, O W Griffith, R C Moschel, S C Schold, D D Bigner, F Ali-Osman.   

Abstract

Previous investigations have revealed that the human TE-671 MR human rhabdomyosarcoma xenograft selected in vivo for melphalan resistance (M. C. Rosenberg, et al., Cancer Res., 49: 6917-6922, 1989) is cross-resistant to a wide variety of alkylating agents and to bleomycin, but is collaterally sensitive to etoposide. Although glutathione levels were noted to be elevated in TE-671 MR compared to the melphalan-sensitive parental TE-671 xenograft, treatment with buthionine sulfoximine to deplete glutathione levels did not fully restore melphalan sensitivity in the TE-671 MR xenograft. The present studies were undertaken to search for additional mechanisms of resistance in the TE-671 MR xenograft. Drug sensitivity testing performed at the dose of agents that was lethal to 10% of the animals revealed that the TE-671 MR xenograft maintained resistance to the bifunctional cross-linking agent 1,3-bis(2-chloroethyl)-1-nitrosourea and was cross-resistant to the topoisomerase I poison topotecan. Treatment with buthionine sulfoximine did not sensitize the TE-671 MR xenograft to 1,3-bis(2-chloroethyl)-1-nitrosourea. Further, even though O6-alkylguanine-DNA alkyltransferase levels were high in both the TE-671 and TE-671 MR xenografts, depletion of O6-alkylguanine-DNA alkyltransferase activity by treatment with O6-benzylguanine substantially sensitized the TE-671 xenografts but not the TE-671 MR xenografts, suggesting an additional mechanism of resistance. Measurement of additional enzyme activities that might be involved in DNA repair revealed significant elevations in DNA polymerase alpha (46 +/- 8 (SD) units/mg protein in TE-671, 69 +/- 6 units/mg protein in TE-671 MR, P < 0.05) and DNA polymerase beta (0.43 +/- 0.01 units/mg protein in TE-671, 0.78 +/- 0.12 units/mg protein in TE-671 MR, P < 0.05) but not DNA polymerase delta or total DNA ligase. Examination of topoisomerases by activity assays and Western blotting revealed a 2-fold increase in topoisomerase II and a 2-fold decrease in topoisomerase I in the TE-671 MR xenograft compared to the parental xenograft, apparently explaining the collateral sensitivity to etoposide and cross-resistance to topotecan. These results suggest that TE-671 MR xenografts contain multiple changes in activities of DNA repair-related proteins and other nuclear proteins that could contribute to alkylating agent resistance.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8012971

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Mechanism of polyoxometalate-mediated inactivation of DNA polymerases: an analysis with HIV-1 reverse transcriptase indicates specificity for the DNA-binding cleft.

Authors:  S G Sarafianos; U Kortz; M T Pope; M J Modak
Journal:  Biochem J       Date:  1996-10-15       Impact factor: 3.857

2.  A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.

Authors:  Andrea E Wahner Hendrickson; Ann L Oberg; Gretchen Glaser; John K Camoriano; Prema P Peethambaram; Gerardo Colon-Otero; Charles Erlichman; S Percy Ivy; Scott H Kaufmann; Larry M Karnitz; Paul Haluska
Journal:  Gynecol Oncol       Date:  2011-11-01       Impact factor: 5.482

3.  Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies.

Authors:  Mamta Gupta; Andrea E Wahner Hendrickson; Seong Seok Yun; Jing Jing Han; Paula A Schneider; Brian D Koh; Mary J Stenson; Linda E Wellik; Jennifer C Shing; Kevin L Peterson; Karen S Flatten; Allan D Hess; B Douglas Smith; Judith E Karp; Sharon Barr; Thomas E Witzig; Scott H Kaufmann
Journal:  Blood       Date:  2011-11-11       Impact factor: 22.113

4.  Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway.

Authors:  Catherine J Huntoon; Monica D Nye; Liyi Geng; Kevin L Peterson; Karen S Flatten; Paul Haluska; Scott H Kaufmann; Larry M Karnitz
Journal:  Cancer Res       Date:  2010-09-14       Impact factor: 12.701

5.  A phase I study of the farnesyltransferase inhibitor Tipifarnib in combination with the epidermal growth factor tyrosine kinase inhibitor Erlotinib in patients with advanced solid tumors.

Authors:  Khalid Jazieh; Julian Molina; Jacob Allred; Jun Yin; Joel Reid; Matthew Goetz; Vun-Sin Lim; Scott H Kaufmann; Alex Adjei
Journal:  Invest New Drugs       Date:  2018-08-31       Impact factor: 3.651

6.  Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT).

Authors:  N R Monks; J A Calvete; N J Curtin; D C Blakey; S J East; D R Newell
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

7.  Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines.

Authors:  U Vanhoefer; M R Müller; R A Hilger; B Lindtner; U Klaassen; N Schleucher; Y M Rustum; S Seeber; A Harstrick
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

8.  Single Nuclear RNA Sequencing Highlights Intra-Tumoral Heterogeneity and Tumor Microenvironment Complexity in Testicular Embryonic Rhabdomyosarcoma.

Authors:  Xuezheng Xu; Zhizhong Liu; Yi Li; Liqing Fan; Shuang Wang; Jie Guo; Yanwei Luo; Hao Bo
Journal:  J Inflamm Res       Date:  2022-01-22

9.  Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.

Authors:  M Sorensen; M Sehested; P B Jensen
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.